Equity Overview
Price & Market Data
Price: $1.07
Daily Change: +$0.0625 / 5.83%
Range: $1.01 - $1.08
Market Cap: $18,290,804
Volume: 61,713
Performance Metrics
1 Week: 33.61%
1 Month: -4.05%
3 Months: -19.32%
6 Months: -34.66%
1 Year: -97.50%
YTD: -8.97%
Company Details
Employees: 7
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.